Ruolan Han, Phd Email and Phone Number
Ruolan Han, Phd work email
- Valid
- Valid
- Valid
Ruolan Han, Phd personal email
Ruolan Han, Phd phone numbers
Ruolan Han, Phd is a 18+ years combined experience in cancer research and drug development at OncoNano Medicine, Inc.. They possess expertise in molecular biology, cell biology, cancer research, neuroscience, drug development and 15 more skills. They is proficient in English. Colleagues describe them as "I've had the pleasure to work with Ruolan for about 4 years. During that time, she showed incredible initiative in driving our research programs and collaborative research. She uncovered several creative ways to evaluate our data from internet research. She always performed when you expanded her responsibilities and was up for any challenge.", "Ruolan was recruited to Salarius at the pre-IND stage to manage IND-enabling nonclinical studies, academic collaborations and grant application. She played an indispensable role for successfully advancing the drug candidate to first-in-human clinical trial. She also made important contributions to fundraising and business development activities. She is a highly intelligent and productive individual capable of working efficiently in a fast-paced cross-functional team environment. I'm confident that she would be an invaluable addition to any team.", and "I worked closely with Ruolan during my tenure as a C-level executive with Salarius Pharmaceuticals and Iterion Therapeutics advancing the respective drug programs through IND. Ruolan played an instrumental role in the achievement of key milestones leading to successful financings (Series A / B) and a public listing on NASDAQ."
-
Vice President, Nonclinical And Translational ResearchOnconano Medicine, Inc. Jun 2021 - PresentSouthlake, Texas, UsI am responsible for setting strategies and overseeing all nonclinical and translational research activities, including ideation, evaluation and early development of new product candidates, and transitioning pipeline products from pre-IND studies to early phase clinical trials. My achievements so far include:• Successfully planned and executed IND-enabling program for the ONM-501, a novel dual STING agonist with an innovative pH sensitive polymeric nano micelle formulation, and transitioned ONM-501 to FIH clinical trial in 2023Q1. • Led the nonclinical team to resolve complex technical challenges during the preclinical development of the OMNI(TM) and ON-BOARD(TM) pH-sensitive polymeric nano-micelle tumor delivery platform technologies.• Oversaw the ideation and selection of additional therapeutic candidates, set development strategies, and made go/no-go decisions based on early development data and competitive intelligence.• Initiated preclinical development program for a novel pH-sensitive nano-micelle encapsulated protein therapeutic product, ONM-412
-
Director, Translational ResearchIterion Therapeutics Jul 2019 - Jun 2021Houston, Texas, UsI was responsible for development and execution of strategies across all nonclinical research areas to transition pipeline compounds from pre-IND studies to early phase clinical trials. My major achievements include:• Major contributor in evaluation and selection of optimum clinical indications. Including assessment of medical need, proposal of clinical development pathways, review of preclinical data for clinical implications, identification of knowledge gaps related to target indications, prioritization of resources needed for specific programs, directing contract research projects and other relevant activities• My contribution resulted in the successful advancement of the lead compound into 3 additional phase 1 clinical studies in AML, pediatric solid tumors, and NSCLC after the first-in-human study. • Served as the scientific lead of the company and managed extensive collaborative relationships with academic, government and industrial partners. Represented the company at scientific conventions and co-authored multiple publications;• Managed internal resources for the R&D function, including budgets, equipment/supplies and people -
Associate Director, Translational ResearchIterion Therapeutics Mar 2017 - Jul 2019Houston, Texas, UsIterion Therapeutics (formerly Beta Cat Pharmaceuticals) is a clinical stage start-up company developing a small molecule inhibitor of the Wnt/Beta-catenin pathway for the treatment of cancer and fibrotic diseases. I’m responsible for strategy-setting and management of translational research programs to advance the investigational compound into early phase clinical trials. My major past achievements include:• Led preclinical programs that resulted in successful advancement of the lead compound Tegavivint (BC2059) into first-in-human Phase 1 clinical trial;• Drafted and submitted 4 non-dilutive grant funding applications and received 2 awards totaling $500, 000; • Served as the scientific lead of the company and managed extensive collaborative relationships with academic, government and industrial partners. Represented the company at scientific conventions and co-authored multiple publications;• Authored and co-authored multiple regulatory/technical documents including IND, Investigator's Brochure, clinical protocols, patent applications, orphan drug application, study reports, etc. • Supported business development activities including market and competition research, international communication for potential China deal negotiation, and scientific support for fund-raising.
-
Associate Director, Nonclinical DevelopmentSalarius Pharmaceuticals Jun 2014 - Jan 2018Houston, Texas, UsSalarius Pharmaceuticals is a clinical stage start-up company developing a small molecule inhibitor of epigenetic enzyme LSD1 for the treatment of cancer. I was responsible for the strategy and management nonclinical development programs to advance the lead compound into early phase clinical trials. My major professional achievements include:• Led preclinical programs that resulted in successful advancement of the lead compound Seclidemstat (SP2577) into first-in-human Phase 1 clinical trial;• Drafted and submitted 4 non-dilutive grant funding applications and received 1 award totaling $200K in value; • Served as the scientific lead of the company and managed extensive collaborative relationships with academic, government and industrial partners. Represented the company at scientific conventions and co-authored multiple publications;• Authored and co-authored multiple regulatory/technical documents including IND, Investigator's Brochure, clinical protocols, patent applications, orphan drug application, study reports, etc.• Supported business development including due diligence for in-license programs, international communication for China deal negotiation, and scientific support for fund-raising. Brought in $200K series-1 investment from an angle investor and a licensing deal to the company. -
Postdoctoral Research ScientistUniversity Of Rochester Mar 2007 - May 2013Rochester, Ny, Us• Research leader and key contributor of a project funded by Susan G. Komen Breast Cancer Foundation: Adverse neurological consequences of breast cancer treatments: causes and prevention• Established the first animal model of “chemo brain” with well-characterized delayed-onset white matter damage endpoints and non-invasive functional endpoints using ABR and DPOAE hearing tests.• Established novel experimental paradigms for screening anti-cancer agents for acute and long-term adverse effects on neural stem cells• Successful collaboration with researchers and physicians from several departments to expand the scope of the study• Trained and supervised multiple students, trainees and technicians• Published in top journals and presented the findings at multiple conferences -
Intern At Office Of Technology TransferUniversity Of Rochester Apr 2007 - Jul 2007Rochester, Ny, UsConducted background research for several new technology transfer cases, communicated with inventors for patent application, and marketed new technologies to several biotech companies for licensing
-
Phd StudentUniversity Of Rochester Sep 2000 - Nov 2006Rochester, Ny, Us• Thesis project: The toxicity of chemotherapy on the central nervous system.• First-authored two ground-breaking research articles in the cellular mechanisms of the “chemo brain”, which were reported by over 100 major news agencies worldwide•Nominee and finalist for Young Neuroscientists’ Workshop hosted by Children's Neurobiological Solutions Foundation• Contributed to the grant application for Susan G. Komen Breast Cancer Foundation funded project.
-
Research AssociateState Key Laboratory Of Genetic Engineering, Fudan University Jul 1998 - Jun 2000Contributed to the Human Genome Project in China by cloning and characterizing several novel human genes;Assisted with the patent preparation of putative novel human genes
Ruolan Han, Phd Skills
Ruolan Han, Phd Education Details
-
University Of Rochester School Of Medicine And DentistryPharmacology -
Fudan UniversityGenetics
Frequently Asked Questions about Ruolan Han, Phd
What company does Ruolan Han, Phd work for?
Ruolan Han, Phd works for Onconano Medicine, Inc.
What is Ruolan Han, Phd's role at the current company?
Ruolan Han, Phd's current role is 18+ years combined experience in cancer research and drug development.
What is Ruolan Han, Phd's email address?
Ruolan Han, Phd's email address is rh****@****rma.com
What is Ruolan Han, Phd's direct phone number?
Ruolan Han, Phd's direct phone number is +158525*****
What schools did Ruolan Han, Phd attend?
Ruolan Han, Phd attended University Of Rochester School Of Medicine And Dentistry, Fudan University.
What are some of Ruolan Han, Phd's interests?
Ruolan Han, Phd has interest in Travelling, Yoga, Dancesport, Reading, Photography, Health And Wellness, Health.
What skills is Ruolan Han, Phd known for?
Ruolan Han, Phd has skills like Molecular Biology, Cell Biology, Cancer Research, Neuroscience, Drug Development, Animal Models, Technology Transfer, Competitive Ballroom Dance, Scientific Writing, Grant Writing, Pharmacology, Photoshop.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial